Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the Alzheimer's Association and the Society for Nuclear Medicine and Molecular ...

And by the time the first symptoms develop, levels of abnormal amyloid-beta are almost peaking ... "If you can reduce tau phosphorylation, potentially there would be less tangle formation and ...

Why have the previous anti-tau therapies shown limited efficacy in vivo? For decades, researchers have produced numerous AD drugs targeting amyloid beta only for them to fail in clinical trials.

This line of inquiry follows animal model and stem cell studies in which efavirenz reduced the accumulation of both amyloid beta and tau. It’s hypothesized that accumulation of cholesterol in ...

Butler was not involved in the work, but he and colleague Eain Murphy at SUNY Upstate Medical University in Syracuse, New York, have likewise found that HSV-1 triggers tau phosphorylation ... no ...

"If you can reduce tau phosphorylation ... slow-wave sleep and elevated levels of tau tangles and amyloid-beta protein. In this latest study, Lucey and colleagues wanted to find out if improving ...

“The discovery that tau phosphorylation can act as a protective ... investigate other pathogens that might interact with tau (or [beta-amyloid]) in Alzheimer’s, and test potential therapies ...

Seventeen clinical scenarios developed for which amyloid or tau PET may be considered. HealthDay News — Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography ...

A study from Washington University in St. Louis found taking suvorexant, a common insomnia medication, for two nights slightly decreased amyloid-beta and tau proteins linked to Alzheimer's.